San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Achieve Life Sciences, Inc. (NASDAQ: ACHV). The investigation focuses on Achieve Life Sciences executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Achieve Life Sciences securities?If you purchased Achieve Life Sciences securities and suffered losses on your investment, join our investigation now: Click here ...

Achieve Life Sciences (NasdaqCM:ACHV) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsJaime Xinos - Chief Commercial OfficerMark Oki - CFOMark Rubinstein - CMONicole Jones - VP of Strategic Communications and Stakeholder RelationsRick Stewart - President and CEOConference Call ParticipantsBrandon Folkes - AnalystJason Butler - Managing Director and Biotechnology Equity Research AnalystJohn Vandermosten - Senior AnalystJustin Walsh - AnalystThomas Gladen - AnalystOperatorGreetings, and w ...

Achieve Life Sciences (NasdaqCM:ACHV) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsBrandon Folkes - Managing DirectorJaime Xinos - Chief Commercial OfficerMark Oki - CFOMark Rubinstein - Chief Medical OfficerNicole Jones - VP of Strategic Communications and Stakeholder RelationsRick Stewart - President and CEOConference Call ParticipantsJason Butler - Managing Director and Biotechnology Equity Research AnalystJohn Vandermosten - Senior Biotechnology AnalystJustin Walsh - Director and ...

Achieve Life Sciences (NasdaqCM:ACHV) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Speaker8Greetings, and welcome to the Achieve Life Sciences fourth quarter and full year 2025 earnings conference call and webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. You will be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. If anyone should requi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 033-80623 Achieve Life Sciences, Inc. (Exact name of the registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 95-4343413 ...

Exhibit 99.1 • Made meaningful progress toward regulatory approval in smoking and vaping: Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24,2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc(Achieve) (Nasdaq: ACHV), a late-stage ...

Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quart ...

SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please u ...

Core Viewpoint - Achieve Life Sciences, Inc. is experiencing notable stock performance, with shares recently surpassing their 200-day moving average, indicating potential investor interest and market activity [2]. Stock Performance - The stock has a 200-day moving average of $4.24 and traded as high as $4.37, with the last trade at $4.14 and a volume of 530,131 shares [2]. - The company has a market capitalization of $220.37 million and a price-to-earnings ratio of -3.00, indicating it is currently not profitable [3][4]. Analyst Ratings - Analysts have varied opinions on Achieve Life Sciences, with Citizens Jmp initiating coverage with a "market outperform" rating and a price target of $19.00 [2]. - Weiss Ratings has a "sell (d-)" rating, while Raymond James Financial maintains a "strong-buy" rating [2]. - The consensus rating is "Moderate Buy" with an average price target of $15.50 [2]. Financial Ratios - The company has a current ratio and quick ratio of 5.14, indicating strong liquidity [3][4]. - The debt-to-equity ratio stands at 0.26, suggesting a conservative approach to leverage [3][4]. Institutional Holdings - Franklin Resources Inc. significantly increased its holdings by 18,747.4% in the fourth quarter, now owning 4,369,193 shares valued at $21.72 million [5]. - Other institutional investors, such as Millennium Management LLC and Hudson Bay Capital Management LP, have also increased their stakes, indicating growing institutional interest [5]. - Institutional investors collectively own 33.52% of the company's stock [5]. Company Overview - Achieve Life Sciences is a clinical-stage biotechnology company focused on developing cytisinicline, a plant-derived alkaloid aimed at smoking cessation [6]. - The company aims to provide an evidence-based therapy to meet the global demand for effective smoking cessation options [6]. Product Information - Cytisinicline acts as a nicotinic acetylcholine receptor partial agonist, helping to alleviate withdrawal symptoms and nicotine cravings [7].

Core Insights - Achieve Life Sciences, Inc. announced new data indicating that cytisinicline is effective in helping individuals quit smoking, including those who have previously failed with other cessation medications and regardless of their quit attempt history [1][4][3] Group 1: Clinical Data and Efficacy - A pooled Phase 3 analysis involving over 1,600 participants demonstrated high quit rates with cytisinicline after 6 and 12 weeks of treatment, showing effectiveness across various prior treatment histories [1][3] - The analysis included participants with different backgrounds, such as those who had used varenicline, bupropion, and nicotine replacement therapy, and categorized them based on their number of previous quit attempts [3][4] - Cytisinicline was shown to benefit individuals regardless of their prior quit history, providing hope for those who have faced setbacks in their attempts to quit smoking [4][3] Group 2: Patient Experience and Safety - Late-breaking survey data from the ORCA-OL study highlighted participant experiences with extended use of cytisinicline, contributing to a comprehensive understanding of its impact on quitting smoking [2][4] - Participants reported meaningful benefits from cytisinicline, including successful quitting and improvements in physical health, emphasizing the importance of patient experience in smoking cessation efforts [5][4] Group 3: Regulatory and Market Context - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline for nicotine dependence, with a New Drug Application submitted to the FDA that is currently under review [7] - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026, for the cytisinicline application, which is based on successful Phase 3 studies and an open-label safety study [7] - The company has also completed a Phase 2 study for vaping cessation, indicating a broader strategy to address nicotine dependence beyond traditional smoking [7]